Pharmaceutical Supply Chain Risks (Research Paper Sample)
The research paper in pharmaceutical supply chain risk focusing in examining trends, risks and challenging in outsourcing biopharmaceutical activities.
Aims and Objectives: Pre-review articles, paper for publication
The area want you to included:
1- first the long tenure of outsourcing in small molecule, well establish
2-look some statistic
3- look at some recent regulator action in small molecule because still present some risks
4- biopharmaceutical , how well place to address the challenging risk to those small molecules
5- managing of distribution on cold supply temperature of biopharmceutical
6- identify the trend where are? and give example
7- identify challenges where are and give example
8- identify the risks where are? and give example
PHARMACEUTICAL SUPPLY CHAIN RISKS
Currently, the pharmaceutical industry is one of the most evolving industries in this century. Unfortunately, the industry has fallen victim to globalization in the supply chain where external service providers are determining the level of operation of the industrial activities. The tremendous changes taking place in this field emerge from changing tastes and preferences of consumers who are the major determinants of how far an industry can go in meeting the needs and demands in the market. Some of the notable changes are inevitable because the modes of operations have now shifted. The responsibility of the business has shifted from that of merely providing goods and services to that of providing quality goods and services to the patient. This has burdened the industry and compelled it to resolve to use outsourcing instead of insourcing. The industry is increasingly outsourcing research activities Contract Research Organizations (CROs) and Contract Development Manufacturing Organizations (CDMOs) to its academic and private contract research organizations (CROs) as a strategy to stay competitive and efficient. The competitive increase in demand for quality services coupled with patient autonomy has left the industry with no choice but to resolve to follow what the market dictates. The present study explores how these changes in the pharma industry affect service delivery and the risk of outsourcing to the future of the industry.
The present overall outlook of outsourcing in the pharmaceutical industry is brighter and promising than ever (Treva, M. 2017, p. 7). Globalization of supply chain ranging from labor to IT services has taken the core of operational activities in the pharmaceutical industry. Pharmaceutical and biotechnology companies have heavily widened their reliance on external service providers for research and development (R&D) and manufacturing services for operations. The major disadvantage for pharma companies is that they do not source drugs substance and R&D from a single vendor. This has had an adverse impact on service delivery and operations because vendors take advantage of the industry and the cost is transferred to the patient. Additionally, Edmunds et al. (R. 2017, p. 3) note that New Health Economy has posed a serious challenge to the pharma industry as patients are now playing a direct role in services they receive. Patients are no longer waiting to receive services at the table, but have gone ahead to demand an understanding of the treatment and medications they receive. The emergence of online service deliveries and consultations has even made it complicated for pharma and biotech companies to blindly serve clients. Patient autonomy has made it compulsory for the industry to do a self-reflection and evaluation before providing drugs to the market. From the CDMO and CRO perspective, quality drug delivery is only possible if there is division in distribution and delivery of services. Pharma companies lag behind in the integration of these services into one system and they do not have time to overtake the changes that have already taken place. This explains continuous outsourcing of CDMO and CRO services and it will only continue being a lucrative business for the external service providers. On the other hand, pharma companies will continue spending billions of money on outsourcing at the expense of affordable insourcing which holds potential, yet underutilized benefits to the industry.
The primary objective of this research study is to develop a risk-based approach to the supply chain in the pharmaceutical industry with the intenti...
YOU MAY ALSO LIKE
- The Nutritional and Pharmaceutical Products of AlgaeDescription: The different species of algae inhabit different habitats such as aquatic, terrestrial and unusual habitats such as symbiotic, parasitic, epizoic, epiphytic...1 page/≈275 words | 3 Sources | Harvard | Health, Medicine, Nursing | Research Paper |
- Investigating Reasons for Holding Excess Inventories at Directorate General of Medical Suppl. . .Description: Investigating Reasons for Holding Excess Inventories at Directorate General of Medical Supplies (Oman) Health, Medicine, Nursing Research Paper...7 pages/≈1925 words | 10 Sources | Harvard | Health, Medicine, Nursing | Research Paper |
- Evidence based practice. Health, Medicine, Nursing Research PaperDescription: For years, social workers have been working exhaustively in assisting and rescuing adolescents in abusive families. In some cases, the young individuals have usually been exposed to both emotional and physical abuses for long spells that they have become traumatized. ...4 pages/≈1100 words | 5 Sources | Harvard | Health, Medicine, Nursing | Research Paper |